Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AIM ImmunoTech has the GF Score of 33, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes AIM ImmunoTech
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
AIM ImmunoTech (FRA:HXB) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
AIM ImmunoTech GF Score Related Terms
FRA:HXB vs RVPH, BOLT, ERNA: GF Score Comparison
For the Biotechnology subindustry, AIM ImmunoTech's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's GF Score distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's GF Score falls into.
AIM ImmunoTech (FRA:HXB) has a GF Score of 33 as of Jul. 14, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on AIM ImmunoTech and its competitors. This is 25% below median its historical median of 44.00. Over the past decade, AIM ImmunoTech's GF Score has ranged from 12.00 to 69.00.
Is AIM ImmunoTech's GF Score too high?
AIM ImmunoTech's current GF Score of 33 is 25% below median its 10-year median of 44.00. Over the past 10 years, this metric has ranged from a low of 12.00 to a high of 69.00. Overall, AIM ImmunoTech has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's GF Score compare to RVPH and BOLT?
AIM ImmunoTech's GF Score of 33 can be compared against companies in the Biotechnology industry. Historically, AIM ImmunoTech's own GF Score has ranged from 12.00 to 69.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current GF Score is 33, which is 25% below median its own 10-year median of 44.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
AIM ImmunoTech (FRA:HXB) has a current GF Score of 33. The stock's GF Value™ is €34.23, compared to a current price of €3.61 — trading 89.4% below its estimated fair value. The current GF Score is 33, which is 25% below median its 10-year median of 44.00. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For AIM ImmunoTech (FRA:HXB), the current GF Score is 33 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (FRA:HXB) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of €3.61 is trading 89.4% below its estimated GF Value™ of €34.23.
Key valuation signals for FRA:HXB:
GF Score: 33 (25% below median its 10-year median of 44.00)
GF Value™: €34.23 vs. price of €3.61 (89.4% below fair value)
No single metric tells the full story. See the FRA:HXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score
Get the complete analysis for FRA:HXB
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HXB has been successfully added to your 
